ArticleJournal for immunotherapy of cancer2024
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
Takayuki Kamikawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this papercites it